Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3007173 | 0.86 | MAPT (0.46) | MAPTATMTP53SMN1; SMN2THRB | |
| SCHEMBL335076 | 0.85 | SMN1; SMN2 (0.50) | MAPTATMTP53SMN1; SMN2THRB | |
| SCHEMBL3016031 | 0.84 | MAPT (0.45) | MAPTATMTP53SMN1; SMN2THRB | |
| SCHEMBL3571150 | 0.84 | MAPT (0.45) | MAPTATMTP53SMN1; SMN2THRB | |
| SCHEMBL333931 | 0.84 | MAPT (0.45) | MAPTATMTP53SMN1; SMN2THRB | |
| SCHEMBL4700108 | 0.84 | PTGES (0.51) | MAPTTP53SMN1; SMN2THRBALDH1A1 | |
| SCHEMBL3009481 | 0.83 | KMT2A (0.50) | MAPTATMTP53SMN1; SMN2THRB | |
| SCHEMBL3012983 | 0.83 | MAPT (0.42) | MAPTATMTP53SMN1; SMN2THRB | |
| SCHEMBL333693 | 0.83 | MAPT (0.43) | MAPTATMTP53SMN1; SMN2THRB | |
| SCHEMBL3012396 | 0.83 | MAPT (0.43) | MAPTATMTP53SMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778633-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-08-07 | — | — | US | disclosed |
| EP-1778633-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2005123674-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, PTGS1, PTGER1 | MAPT 3535/4885ATM 3994/4885TP53 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.